Navigation Links
BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
Date:9/22/2009

, and expectations related to clinical trials of PEG-PAL. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials related to PEG-PAL; the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory agencies, particularly with respect to PEG-PAL, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                       Media
    Eugenia Shen                    Susan Berg
    BioMarin Pharmaceutical Inc.    BioMarin Pharmaceutical Inc.
    (415) 506-6570                  (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
2. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces FDA Approval for Kuvan
5. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
6. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
7. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
8. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
9. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
10. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
11. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Dr. Michael Gabriel of a prominent Staten ... study, which shows how grief in pregnancy may cause obesity ... According to US News , "Unborn children ... others to grow up overweight or obese, even if that ... specific types of stress that caused obesity: "Children whose biological ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
(Date:7/24/2014)... Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... First quarter overview: , Revenues of $47.5 million, ... Diluted EPS of $0.21, up 50% over last year,s ... market revenues of $7.2 million, up 20% over last ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Bioness Inc., today announced the commercial release of its ... Drug Administration (FDA) earlier this year, the L300 Plus combines ... thigh cuff to activate even more of the nerves and ... The L300 Plus is intended for people ...
... LLC , a drug research and development company focused ... its compound CM-182 demonstrated positive results for reduction in ... screening was performed by the contract research organization, Cerca ... C57BL/6 mice exhibited a dose dependent reduction in hyperactivity ...
Cached Medicine Technology:Bioness Inc Announces Availability of L300 Plus System 2Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity 2
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are ... a younger appearance. The Cherry News company has published ... and women explore the availabilities from U.S. retailers at ... in the posted guide on the Cherry News website ... drawback to some natural ingredient formulas is the high ...
(Date:7/27/2014)... CA (PRWEB) July 27, 2014 Ticket Down ... Tickets at The Forum in Inglewood, California on November 15th. ... and diehard fans can expect to hear songs from this amazing ... of Summer concert in Inglewood, California at The Forum will be ... starting at 10:00 a.m. today local time TicketDown.com. This popular ...
(Date:7/27/2014)... The constant expansion of companies across the globe has ... Additional factors that have increased this demand include the ... communication, learning and development, security and safety, and knowledge ... enterprise video market value has crossed $11.21 billion in ... 2018 with a compound annual growth rate (CAGR) of ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market ... Type (OE & Aftermarket), Filter Type (Oil & Fuel), ... Trends & Forecast to 2018”, defines and segments the ... and forecasting of the global volume and revenue. The ... a revenue of $6.1 billion in 2018, while fuel ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The European Bromine ... with analysis and forecast of revenue. , Bromine market in ... France, Spain, and UK. Germany and France that forms a ... and its derivatives in Europe. , Browse through the ... idea of the in-depth analysis provided Browse through the TOC ...
Breaking Medicine News(10 mins):Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
... risk factors for heart disease, including blood pressure and ... Association recommended Monday in new guidelines for the prevention ... the panel, observed that heart disease actually begins in ... make large changes in behavior early on. He said ...
... to a new research, a daily dose of a soybean ... "bad", or LDL, cholesterol levels in young men. Functional foods ... essential nutrients. //There has been a trend of adding value ... For example, Benecol Spread is a margarine that contains phytosterol ...
... Researchers say a daily teaspoon of lemon-flavored cod liver ... may help prevent middle ear infections in children. New ... infection,// required fewer antibiotics and had fewer ear infections ... oil, which has vitamins A and D and omega-3 ...
... Hopkins found a new study shows some cancer patients ... from treatment with the drug, interferon.,Past research has suggested ... B-cell non-Hodgkin's lymphoma's. //A patient with both of these ... patient responded causing researchers in Paris to study whether ...
... a new study which suggests hormone suppression therapy ... chances of living free of the disease.Michel Bolla, ... potential benefits of suppressing the male hormone androgen, ... testosterone, among 400 patients in advanced stages// of ...
... to take antibiotics before dental cleaning to reduce the ... drugs do not take them, sometimes because their doctors ... realize that the antibiotics are warranted, according to a ... that they say may increase compliance with the antibiotic ...
Cached Medicine News:Health News:Heart attack risk starts at 20 2Health News:Hormone Therapy applicable for Prostate Cancer 2
... This remarkable anti-reflux valve is ... housing which prevents the valve ... when in sitting or reclining ... self-cleaning and interference free ensuring ...
Intermittent catheter - SpeediCath™ is pre-hydrated and ready to use right out of the package. Just open, cath and get on with your life....
The Medtronic® Resting Heart™ System offers a new approach to reducing cardiac surgery morbidity....
This adapter features a female luer on the single leg. A rigid "Y" has two legs with white clamps and terminate with male luers....
Medicine Products: